// App-Quantinova.ai

2147 : Comparison of published noninvasive biomarkers to reliably exclude severe fibrosis in NAFLD patients

Researchers

Presenter

  • Peter J. Eddowes

Principal Investigators

  • Michael E. Allison

  • Emmanuel Tsochatzis

  • Quentin M. Anstee

  • Indra Neil Guha

  • Jeremy F. Cobbold

  • David A. Sheridan

  • Valerie Paradis

  • Pierre Bedossa

  • Philip Newsome

Medical Centers

  • NIHR Biomedical Research Unit and The Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom

  • Department of Radiology, Addenbrooke's Hospital, Cambridge, United Kingdom

  • Liver Failure Group, UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom

  • Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom

  • NIHR Nottingham Biomedical Research Centre, NHS Trust and University of Nottingham, Nottingham, United Kingdom

  • Department of Gastroenterology, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, United Kingdom

  • Institute of Translational and Stratified Medicine, Plymouth University, Plymouth, United Kingdom

  • Department of Pathology, Physiology and Imaging, Beaujon Hospital Paris Diderot University, Paris, France

Locations

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Nonalcoholic fatty liver disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved